Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes but put out a release of some sort, at least just saying its halted at least.
Thanks Voova. Still what does that sentence mean. Really perturbed this morning. We are a dual listed company and I should not be having to copy and paste into Google translate to figure out what the hell is going on. Or be asking others to do translating stuff for me. A halt is normally for a pretty significant thing, An offering has never halted this thing before. But why can we get no info in English there management. But maybe I'm just groggy still and am not following what is going on.
If that's all it is, why the halt. I'm too confused. Has to mean more that that. To a partner??? Lonza??? Lmao
Anyone care to translate this page PLEASE.
http://mayafiles.tase.co.il/rpdf/1128001-1129000/P1128249-00.pdf
Well I guess they got sick of missing the milestones so why put them in. I'm more concerned with this halt. Trying to copy and paste into Google translate from my phone. Not having much luck.
What was the lie Voova
Where did you find that description Nem. Was that what is says under event on TASE. Goes to Hebrew page. Just waking up and am trying to figure out why the halt. Not sure I follow.
Again, zero logic. Again, zero facts. Again, zero thought. Enough already!!! Give away a portion of our most prized possession, the 3d bioreactor. You know, the one that can only grow MSC's. You know, because IR answered that question for you, but refused to answer my exact question. Easily scalable is what they've said for years. Logic evades the ones who read tea leaves. Lmao.
Maybe...but this company would have closed up shop many years ago if you were. Lmao.
I figured you would. Lonza IS a global company with over 100 locations worldwide. None located in the Middle East. What logical spot would there be to open up in the Middle East? Tehran? Mosul? Egypt?
Again, you claim Pluristem can only grow MSC's in their bioreactors. A question IR did not want to respond to. Have yet to get an single answer to any of my emails. Not even an acknowledgment of any email. Good job IR. But maybe they read these boards and know who I am. Don't see a reason whatsoever that Lonza would want to partner. I know, you said they want to partner so they can have Pluristem as their customer. Very logical explanation. HA!!!
The need for any significant order that they can't handle right now, is unlikely. Any sort of stockpiling contract they 'may" get, would I'm sure, be of a smaller size. One to cover military personnel and such. After/if they get FDA approval, contracts for other countries and for civilian population numbers, would be much bigger. For now, nobody but the U.S. government can order this product. But with the addition of bioreactors, near term quantities could be covered. Get the first stockpiling contract, THEN look at ways to handle expected growth, if existing facilities will not be able to meet the need in the near future. They would have at least six months to a year to figure out that great problem to have.
I would email IR about it, but that is pointless as they are useless. So I will stick to logic as I always do, and leave the trustworthy tea leaf reading for you alone. You state little to no evidence pointing to any sort of benefit would be beneficial to both. Just that they're opening in Haifa, and an ex-employee is in charge. Coincidence is for the ill informed, IMO. Logic rules!!!
Just like your post that followed, you speculate with pretty much zero to back up any claim you make. Compassionate use...must be us...see we can cure genetic disorders. LMAO
Found something looking back at an interview with one of the twins that is very relevant in this Lonza talk of late.
"We have the capacity to make 150,000 doses of commercial grade PLX cells at this time, and to increase capacity we need only scale out with additional bioreactors. We do not need to modify the patented production technology. "
https://marketexclusive.com/exclusive-interview-pluristem-therapeutics-inc-nasdaqpsti-president-yaky-yanay/2016/11/
So by the sounds of it, this 150,000 dose capacity, is hindered only by the number of bioreactors, not space. How many bioreactors our facility could hold is the only question. That 150,000 number was there when the original facility was built. It was expanded as well. Right now there is approximately 5000 square feet of clean rooms. That is a fair size and like I said before, those bioreactors aren't that big.
So I do not expect any Lonza partnership any time soon. Their opening in Haifa, is just to source talent and resources from that high tech area.
Ya mite want to chek ur math dere eh!!!
I have often thought of what you said. How is being an Israeli based company is affecting this company. Especially in light of the protectionist leader in power now.
But could that also hold true with pretty much most of our management team's lack of pharma experience? This is a world of 1%'s. Big ego's, bigger money, and powerful corporations. To come from a background of engineering and manufacturing vision systems for the textile industry, is a completely different world than they're in now.
Just some food for thought. Again, I will give them to the end of the year. Hit some of the projections people are making, and I will be happy enough that all of this will be a moot point. Sitting lower than $2 by the end of the year, there should be hell to pay.
I may have made your point, but I think you missed mine. LOL The number of trials was irrelevant, it's just what got me looking. I do believe 5 of them were ongoing before Pfizer partnership as the are all 1/2. Could care less though.
We are a PHASE 3 company. They are a phase 1/2. When I say phase 1/2, that's what their trials are. No completed phase 1's moving to 2. All starting 1/2. How did the get any sort of deal like that? VAST INDUSTRY EXPERIENCE!!! What partnership do we have. A potential $11 million investment by a venture fund to start up a new company. And we can't even close that.
That proverbial partnership carrot has been dangled in from of our noses for way too long. We are a few days from being just 2 months away from the end of the promised year. If nothing comes by then, they should be tossed out for sure. The whole bunch of them.
I remember a majority of people calling for their heads if things don't happen this year. I don't want people to forget like it seems like they have. You think I'm hard on management now.
Yes they may get us to the promised land. Only thing is, we should have been there long ago. Just think. Phase 1/2. Seeing that made me feel ill. That's the first step from preclinical. Pfizer wow. Imagine seeing Pluristem partnered with Pfizer, Celgene, J&J. Any one of those bring so much credibility. What do we get. Sosei venture capital. Soeswho?
Obviously there is the government which will likely come through some day. Hopefully soon. But if anyone could get this contract delayed until next year, management can. It's what they do best unfortunately
Sorry one thing I forgot to mention. A 64% tute ownership.
Midas, your call to show you another company with similar amount of trials, got me looking to a list I kept of someone's top ten biotechs. Every once in a while I take a look. It's been a while but I notice Sangamo. Now I don't follow them or know much about them, but here are some things I've taken a look at for the last hour or so. Sorry for this large post, but it is quite interesting, and a point regarding Pluristem near the end.
They have 7 ongoing trials, mostly phase 1/2 with some preclinical. They have a market cap of a billion, with a quarter billion in cash. They have 24 million in revenue (don't know from what). They partnered with Pfizer with an upfront payment of $70 million and almost half billion in milestone payments.
They were at a similar market cap to Pluristem a year ago, and that's why they caught my eye. What happened where a phase 1/2 company could quadruple their market cap. I noticed in 2016, they did a revamp of management, including their CEO. If you look at their management, every single one of them came from this industry. Eleven of the twelve have vast experience in the pharma industry. All but their CFO.
Now have a look at the CEO's Sandy Macrae's pedigree. Various positions at Takeda and GSK. Over 20 years experience. This is what management should look like. He has taken this phase 1/2 company to places I'm not sure they should be.
And what are we? A phase 3 company!!! This is exactly what I mean when I talk about management. Many state how they were visionaries Maybe I don't give them enough credit for that, which I should. They had a vision and took it a long way. A huge accomplishment by any standards, and should be rewarded. But visionaries don't necessarily make the best breed to run a company.
But they have indeed been rewarded with a boatload of shares for the work they have done to bring us to this point. Now if, by the end of the year nothing does come about of epic proportions, I think their time has past. Experience in this industry is a must, with the connections and knowledge that this unique industry brings.
They would be considered pioneers in this industry if Pluristem's potential is realized. A place in the history books. They have millions of shares, so their hard work in the early days, would make them rich like few others. Sometimes the smartest people are the ones who realize they're not the smartest.
I don't know how Sangamo did this revamp, but they did get this done, and have reaped significant gains from it. If Pluristem's management doesn't prove themselves by the end of the year, I hope it happens with us. Short leash I say.
BTW. Have a look at their 1 year chart. I'm looking for a similar gain by the end of the year. I will make a call of $5. GLTA
I somewhat agree with your generalization of CC's. I used to listen to all the UT conference calls, waiting to hear about Pluristem. I did find them pretty informative. I seem to recall some numbers getting thrown out with regards to enrolment numbers.
But in the very least, it shows transparency and gives analysts some time to get some of their questions answered. They're way more important than us. Not expecting much if any of the mountain of questions I would like to get answered. But that is the norm for companies and they really should do this. Would give us all something to look forward to as well.
This arm chair CEO would have been conducting CC's and being very transparent, eliminating the need for armchair CEO's like you say. All we ever get to do is speculate what is best using logical thoughts.
That subject only turns ugly, when one individual gets involved. I have thought lots on this topic, and have a couple of scenarios. Neither one bad.
They have been selling enough to keep cash on hand stable, in which we are seeing little dilution, but enough to keep them with a sustainable business model for the foreseeable future. Would also bode well in thinking management is expecting some sort of contract.
The other being they have sold substantially more, in which they have gotten better coin than their Chinese partnership on a per share basis (obviously depending when and how much they sold in this recent run.) A little bigger on the dilution front, but the extra cash would go a long way in mitigating near term risks. And as a bonus, that would mean we were able to make this run, with a big seller in our midst.
Either one, or somewhere in the middle, will be beneficial to us. We will all see in just over a couple of weeks, what scenario is true. All of course IMO.
What Spidey said...
Excellent point on that one that was missed. Could be a ramping up getting ready to advance quickly for when phase 2 comes about. Only thing I see with that is why they haven't released any update on this trial then. Maybe we will get that soon. This year would be great!!! But a great point and hoping you're correct.
I am thinking along the lines of safety profile for R18. Human safety data alone will be much more important than just NPH safety. Some competitors already have human safety issues addressed.
Also the effectiveness in repairing bone marrow would help. I'm not too knowledgable in the HCT trial. Not sure how these two studies relate in this matter, but I would think they are similar. I'll leave that one for our resident expert.
Points well taken Spidey thank you. I concede, I was a little harsh.
In the very least it will speed things up or at least can't hurt, regardless of the reason. And yes, the significance with regards to ARS is monumental. So speed it up any way you can.
One question I have is how costly it is to add sites. Is it minimal, or is it only when a patient becomes enrolled, in which case there would be minimal impact on cost. Any ideas on that one?
I know,,,just trying to stay positive and hopeful that we one day move from here on some real news and never look back. I know I seem negative most of the time, but it's mainly to keep a balanced view, keeping me from shovelling more dough in this thing than I should. Still very risky, but the potential could be a once in a lifetime opportunity. Been on the cusp of something for far too long, but that cusp remains so very near still.
That being said, if this news pushes us up nearly 4% through the $2 mark like pm is showing, I'll take news like this every day.
You beat me to it Spidey. Excellent post. The cries of success are totally premature to say the least.
One thing I might add is that this is the study we hired the top tier, secretive CRO. You would think with their global reach and connections, they would have this trial moving at a quicker pace. Maybe I'm unsure of the purpose of a CRO, I don't know.
This study is open label like you said. If the results were anything extraordinary, you would have to think this study wouldn't need additional sites and enrolment would be happening at a quicker pace. Only question with regards to that is how many people suffer from this that has been ongoing for at least 6 months. But it is only 30 they need.
That is why this company could desperately use some help in the transparency department. A CC or heck, even a presentation or something showing recruitment status on this trial. The way I look at it is if they were chugging along, they would be put in there somewhere, just like the IC trial did eventually.
I try, but can't find any reasonable explanation how or why this news would be positive in the least. Maybe others can change my mind with thoughtful input. No negative sallies, or pure garbage like that.
Not looking forward to their next presentation's upcoming milestones. Better not be changed AGAIN, for any of them.
Whoa whoa whoa. Are those tea leaves aligning. Very interesting. Could be TEVA too. They're listed on both exchanges as well!!! Maybe THEY'RE the big pharma controller. They knew all along Pluristem was the real deal, did a head fake with Meso to make it easier to manipulate Pluristem by keeping the attention away from them. And maybe now, they're going to try and do a hostile takeover of Lonza, so they can have Pluristem as their customer. How did I not see this before!!! Pure genius!!!!
Well said. The years of the controller conspiracy theory, are just everyday markets. Pluristem was such a bore for so long. Before this run, the 52 week spread was nearing 50 cents with volume of around 50 thousand most days. Easy to manipulate, but even then there comes a time when it becomes pointless.
Let it run and get some excitement back in this stock. Get the volume and the volatility back, allowing for some serious profits for those that play this game. I do think the three firms hired to do this ATM raise have had a significant impact on getting us to where we are. That's what they're there for. The more they raise, the bigger the cut. Glad they put it out to three of them. Smart move IMO.
Yes there will always be some profit taking happening, taking a little steam away. But very necessary to keep the upward momentum going.
We seem to be drifting back some today. Pluristem must have turned the ATM off. Cmon turn it back on. We need more selling to lift us back to $2. It's all about supply and demand...the bizarro world kind. Lmao
You just don't get it. Only one that's delusional in this dumb conversation and it sure isn't me. I never once said they never were. I don't know, you don't know, nobody does. You forgot about mm's selling. Ever hear of them? I'm done talking to sticks really.
Not nuts at all. Only you can't seem to grasp anything. Who says they didn't sell all that they needed earlier in the run. Maybe they are still selling most likely are. But YET AGAIN, you miss the point. Nobody knows except management and hired firms. For you to say like you know, is nothing but a downright LIE!!! I've got to give ya the Moe two fingers to the eye there Curly.
I really don't think you see what they were getting at. That YOU have no idea if or when they are selling them like YOU claim. Again like a million times before, a simple IMO puts it all to rest. Unless you have inside info, you are simply guessing. Yes they sold before as obviously stated in the last report. But doesn't mean they are or aren't now. Wow.
Stick a fork in this topic PLEASE.
I'm rubber you're glue...wow what a child. Nothing intelligent ever said. Lmao. Defeat doesn't sit well with some people does it.
Nothing to say on that one except LMAO. I guess that's what you meant by expensive software. Not for their bioreactors, but to beat the streets algorithms by selling to raise prices. Maybe they should purchase Watson. Lmao
They got their facility up and running for a relatively cheap price. With a big contract, there would easily be non diluting ways to make it happen. If clues were shoes, some would be barefoot always.
It's pointless trying to talk with them. I use them as multiple people post under that handle. Guaranteed. It's like talking to a stick. It's as useless as an a-hole right here (elbow). Not replying to "anyone" in specific, just the whole world. Lmao
I hear you loud and clear. Cash is an absolute necessity here. I just want to stay away from that R/S nightmare as much as possible. But look forward to seeing actual numbers from the ATM soon enough. Anyone's projections are just pure speculation, mine included.
They got their $2 close. They must have been selling like crazy near the end to make that happen. Good job Pluristem. Can't believe I had the supply and demand thing backwards my whole life. Thanks Allo
So again, they are selling to get to that $2 level. Wow amazing.
Hi n3
Yes selling into this rising tide is ok if they are. They were going to sell $30 mil to the Chinese at a lower price. I just think if they are selling more than they need to, it does not bode well for a government contract coming soon, or with the $$$ most are hoping for. But I will take the excess cash in hand if it is continuing. It is needed. Just want dilution to be as little as possible.
You berate and belittle so many posters, yet most of the very few posts that actually have any personal input into them, are shot down over and over until you stop trying to save face and give up.
Please thy genius. How on earth does Pluristem selling shares, provide support under the stock. I guess Sabby was a big help for us, selling their 5 million shares. I guess we would have been at a nickel without their "support". Thanks so much Sabby.